MPS 2 Disease Statistics in US | Key Facts

What Is MPS 2 Disease?

Mucopolysaccharidosis Type II (MPS II), more commonly known as Hunter syndrome, is one of the rarest and most devastating inherited diseases recorded in the United States — a progressive, life-limiting lysosomal storage disorder that primarily strikes young boys and robs them of physical function, neurological development, and years of life, often before they reach adulthood. Named after Dr. Charles Hunter, the Canadian physician who first described two affected brothers at a Royal Society of Medicine meeting in London in 1917, MPS II results from a single defective gene on the X chromosome that prevents the body from producing a critical enzyme called iduronate-2-sulfatase (I2S). Without this enzyme, complex sugar molecules called glycosaminoglycans (GAGs) — specifically heparan sulfate and dermatan sulfate — accumulate inside the lysosomes of cells throughout every organ system in the body. The result is a cascade of progressive, irreversible damage to the brain, heart, liver, lungs, skeleton, joints, skin, and airways that begins silently at birth and becomes visible, then devastating, within the first few years of life.

In the United States, approximately 500 children are living with MPS II at any given time, out of an estimated 2,000 patients worldwide. It is classified as an ultra-rare disease, with an incidence rate estimated at approximately 1 in 100,000 to 1 in 170,000 male births, and is the only X-linked mucopolysaccharidosis — meaning it affects almost exclusively boys, because they carry only one X chromosome. Girls who inherit the faulty IDS gene on one of their two X chromosomes typically remain carriers without symptoms, though rare female cases occur due to X-chromosome inactivation. The disease is marked by two main phenotypes: a severe (neuronopathic) form affecting roughly two-thirds of patients, where progressive cognitive decline leads to death in the first or second decade of life; and an attenuated (non-neuronopathic) form, where intelligence is generally preserved but serious physical complications still cause premature death, often in the third to fifth decade. As of April 2026, the US is on the cusp of a potential historic breakthrough: tividenofusp alfa (DNL310), the first-ever blood-brain-barrier-crossing ERT for MPS II, has its FDA decision date of April 5, 2026 — a moment the entire MPS II community has been waiting years for.

Interesting Facts About MPS 2 Disease in the US

Before going section by section through the statistics, here are the most important and verified facts about MPS II (Hunter syndrome) in the United States — the numbers that frame the full picture of this rare disease.

Source: EveryLife Foundation for Rare Diseases; National MPS Society / Orphanet Journal of Rare Diseases (2021, PMC); Wikipedia Hunter syndrome; MedlinePlus Genetics; NCBI StatPearls; NCBI GeneReviews (Jan 2025); Baby’s First Test / HRSA Newborn Screening; PMC Genetics in Medicine (2023); IMARC Group Hunter Syndrome Market; PMC Orphanet J Rare Dis (2025 — Hunter Outcome Survey adults)

Reading these facts together, what immediately stands out about MPS II in the United States is the sheer weight that falls on so few families. 500 children sounds like a small number, and it is — until you understand that each of those 500 represents a family confronting a progressive, life-limiting disease with no cure, navigating a medical system where most primary care physicians have never seen a single case, fighting to access a treatment that costs hundreds of thousands of dollars a year, and managing the relentless advance of a condition that can take a child from apparent health to severe disability in the span of a few years. The ultra-rare disease label that technically applies to MPS II — defined in US law as fewer than 200,000 cases — understates the reality, because MPS II is not just rare, it is ultra-rare: far smaller in prevalence than even most rare diseases. That rarity is both a medical challenge and a policy one, because it makes clinical trials harder to run, makes physician familiarity almost impossible to build, and means that the entire patient community is small enough to fit in a moderate-sized school gymnasium.

The news on the treatment horizon in 2026 is the most significant development in MPS II management since Elaprase was approved in 2006. The FDA’s April 5, 2026 decision date for tividenofusp alfa is genuinely historic: if approved, it will be the first therapy in history capable of delivering the missing I2S enzyme into the brain, potentially addressing the cognitive decline that has been the most devastating and previously untreatable aspect of severe MPS II. For the two-thirds of patients with the neuronopathic form — boys who currently develop normally for a few years and then regress, losing skills, cognition, and ultimately their lives in adolescence — that approval could represent a fundamental shift in what doctors can offer at the time of diagnosis.

MPS 2 Disease Epidemiology and Prevalence Statistics US

Source: Orphanet Journal of Rare Diseases (PMC 2021) — Epidemiology of MPS in the United States; EveryLife Foundation for Rare Diseases; Hunter syndrome Wikipedia; NCBI StatPearls; PMC Genetics in Medicine (2023); Takeda MedConnect Hunter Syndrome Clinical Reference; PMC 100 Years of MPS II Research (2020)

The US epidemiology picture for MPS II is complicated by a well-documented undercount problem. The National MPS Society database study covering 789 MPS patients over 20 years (1995–2015) represents the most comprehensive US incidence and prevalence analysis ever conducted, but its authors acknowledge significant limitations: there is no national mandatory reporting system for MPS in the United States, and patients who are never diagnosed — either because they live in areas with limited access to metabolic disease specialists, or because their early symptoms are attributed to more common conditions like recurrent ear infections, developmental delays, or ADHD — are simply not captured in any registry. The study itself found US prevalence roughly half that of Scandinavian countries, which the researchers attributed partly to the US’s larger and more diverse population, but also partly to these detection and reporting gaps.

The incidence figures also vary significantly depending on the source — ranging from 0.26 per 100,000 live births in the US National MPS Society dataset to approximately 1 in 162,000 live male births cited by StatPearls, reflecting different denominators (all live births vs. male live births only), different time periods, and different data sources. What all sources agree on is that MPS II is an ultra-rare disease that affects a very small absolute number of individuals, predominantly male, and that the US disease burden — while smaller in relative terms than some other countries — represents a concentrated set of seriously affected children and families who bear an enormous physiological, emotional, and financial burden from a condition most people have never heard of.

MPS 2 Disease Symptoms and Clinical Manifestations Statistics

Source: NCBI StatPearls (MPS II); MedlinePlus Genetics; Wikipedia Hunter syndrome; Hunter Outcome Survey PMC (2025 — 373 adult patients); Cleveland Clinic Hunter Syndrome; NCBI GeneReviews (January 2025); PMC European Journal of Paediatrics (Hunter clinical review); Medscape MPS II Clinical Presentation

The clinical picture of MPS II is one of a disease that hides in plain sight for years before its true identity is revealed. In the earliest months of life, children with MPS II appear completely normal — there are no signs at birth. The first symptoms, typically recurring ear infections, runny nose, and inguinal or umbilical hernias, are so common in the general paediatric population that they generate no particular alarm in a primary care setting. Abdominal hernias in a young boy, frequent ear infections, and a slightly protruded belly — taken individually, none of these symptoms announces a lysosomal storage disorder. It is only when they accumulate, when the facial features begin to coarsen, when the growth curve starts to flatten, when speech development lags or behavioural problems emerge that a clinician experienced in rare disease begins to connect the dots. By then, in the severe form, months or years of opportunity for earlier intervention have passed.

The 63% rate of valvular heart disease and the near-universal airway involvement represent the two organ systems that most directly determine survival. The thickening of heart valves by accumulated dermatan sulfate — which is a major structural component of cardiac valve tissue — is a slow but relentless process that begins in early childhood and may require valve replacement surgery in some patients. The airway obstruction driven by enlarged tonsils and adenoids, thickened tracheal walls, and macroglossia creates one of the most complex anaesthetic management challenges in paediatric medicine: every surgical intervention in an MPS II patient carries significant airway risk, which is why specialist centres familiar with these complications are strongly preferred for any procedure. The hearing loss figure of 38.6% of adults using hearing aids — from the most current Hunter Outcome Survey data published in 2025 — underscores how comprehensively the disease affects sensory function even in patients who survive into adulthood on ERT.

MPS 2 Disease Diagnosis Statistics in the US

Source: NCBI GeneReviews MPS II (January 2025); NCBI StatPearls; HRSA Newborn Screening RUSP page; Genetics in Medicine (PMC 2023 — NBS recommendation paper); PMC Illinois NBS update; EveryLife Foundation for Rare Diseases; Orphanet J Rare Diseases (MPS II epidemiology); Medscape; Cleveland Clinic

The diagnostic journey for a child with MPS II has historically been one of the most fraught and delayed in all of rare disease medicine. The average gap between symptom onset (age 1.5–1.6 years) and confirmed diagnosis (age 3.2–3.3 years) — a delay of roughly 18 months even in recent real-world data from the Hunter Outcome Survey — represents 18 months during which GAG accumulation continues unchecked, organ damage progresses, and irreversible changes may be occurring in the brain of a child with the severe form. In attenuated MPS II, the delay can be even longer: years of symptoms attributed to developmental variation, orthopaedic complaints, or respiratory issues before the underlying metabolic cause is identified. Early diagnosis matters enormously because current ERT — and potentially the new brain-penetrant ERT awaiting FDA decision — works best when started before significant damage has occurred.

The addition of MPS II to the Recommended Uniform Screening Panel in August 2022 was a landmark achievement for the patient and advocacy community, driven by the availability of an effective treatment (Elaprase since 2006) and a growing body of evidence that presymptomatic treatment leads to meaningfully better outcomes. Illinois and Missouri were the pioneering states, beginning newborn screening for MPS II in 2017 and 2018 respectively — years before the national recommendation — and their data, including the Illinois experience of identifying 3 true MPS II cases among 339,269 screened infants, provided critical real-world evidence for the ACHDNC review process. The challenge now is implementation: while MPS II is on the RUSP, individual states control their own screening programmes, and not all states have yet operationalised MPS II newborn screening as of 2026.

MPS 2 Disease Treatment Statistics in the US

Source: NCBI GeneReviews (January 2025); Genetics in Medicine PMC 2023; HRSA NBS evidence review; Prime Therapeutics High-Cost Therapy Profile (November 2025); Denali Therapeutics press release (December 30, 2025); GlobeNewswire; REGENXBIO CAMPSIITE trial results (February 2024); Hunter Outcome Survey PMC (2025); Labiotech.eu (February 2025); Wikipedia Hunter syndrome; NCBI StatPearls; PMC European Journal of Paediatrics

The treatment landscape for MPS II in 2026 is at an inflection point unlike any moment since Elaprase’s 2006 approval. For nearly 20 years, the standard of care has been idursulfase — a therapy that meaningfully extends life and improves physical symptoms but is fundamentally limited by its inability to cross the blood-brain barrier. Every child with the neuronopathic form of MPS II who has received weekly Elaprase infusions since 2006 has had their body treated but their brain left behind. The enzyme gets into cells in the liver, spleen, joints, and heart — but not into the neurons where heparan sulfate accumulates and destroys cognitive function. That limitation is the reason why ERT, for all its demonstrated benefits, has not changed the fundamental outcome trajectory for severe-form patients: they still decline cognitively, they still lose skills, they still die young.

Tividenofusp alfa is the most serious attempt yet to solve that problem. Denali’s proprietary Enzyme Transport Vehicle (ETV) platform engineers the I2S enzyme to bind to receptors on the surface of brain capillary cells, essentially hitching a ride across the blood-brain barrier into the CNS. The Phase 1/2 results published in the New England Journal of Medicine on January 1, 2026 showed reduced CSF GAG biomarkers, improved hearing, and — most significantly — improvements in cognition, suggesting that the drug is doing something in the brain that idursulfase never could. The FDA PDUFA date of April 5, 2026 — just two days from the date this article is written — means the decision is effectively imminent. Approval would mark the most significant advance in MPS II treatment in two decades. The gene therapy programme RGX-121 from REGENXBIO adds a second potential paradigm shift: an intracisternal one-time gene delivery that in Phase III achieved an 85% reduction in the brain disease biomarker D2S6, with 80% of treated patients discontinuing IV ERT entirely.

MPS 2 Disease — Phenotypes and Prognosis Statistics

Source: NCBI GeneReviews (January 2025); NCBI StatPearls; PMC 100 Years of MPS II Research (2020); Genetics in Medicine PMC (2023); PMC Hunter Outcome Survey adults (2025); NINDS Mucopolysaccharidoses page; Wikipedia Hunter syndrome; PMC European Journal of Paediatrics

The two-phenotype framework for MPS II is clinically important but conceptually oversimplified, as researchers and clinicians have increasingly recognised over the past decade. MPS II is better understood as a continuous spectrum of disease severity, rather than two cleanly separate categories. A child classified as “attenuated” may still have severe joint disease, cardiac complications, and hearing loss that profoundly affect quality of life and require constant medical management. A child initially classified as “severe” based on early behavioural or cognitive changes may have a slower rate of neurological decline than expected. The correlation between specific IDS gene mutations and ultimate disease severity — the so-called genotype-phenotype relationship — is complicated by the fact that over 600 different mutations have been identified in the IDS gene, and for the majority of these, reliable severity predictions cannot be made.

What is clear from the Hunter Outcome Survey data — the largest and most comprehensive real-world registry of MPS II patients, now encompassing decades of follow-up across multiple countries — is that even adult patients classified as “attenuated” carry a substantial burden of disease. 47% undergoing at least one surgery in adulthood, 38.6% requiring hearing aids, and 23.6% having cognitive impairment (despite the attenuated classification) paint a picture of a condition that does not stop being serious just because a patient survives past childhood. The attenuated form of MPS II is not a mild disease — it is a less rapidly fatal one, which still demands intensive multidisciplinary management and imposes enormous burdens on patients, families, and healthcare systems throughout a patient’s life.

MPS 2 Disease Genetics and Molecular Statistics

Source: NCBI StatPearls; NCBI GeneReviews (January 2025); MedlinePlus Genetics; PMC 100 Years of MPS II Research (2020); Takeda MedConnect; Wikipedia Hunter syndrome; PMC Epidemiology MPS II review

The genetics of MPS II are defined by extraordinary heterogeneity, which creates both clinical and therapeutic challenges that distinguish it from many other single-gene disorders. Most common inherited diseases are caused by a relatively small number of recurring mutations that can be efficiently screened for in high-risk populations. MPS II instead presents clinicians and genetic counsellors with a catalogue of over 600 different mutations scattered across the IDS gene, the vast majority of which occur in individual or small numbers of families and for which no reliable severity prediction is possible based on genotype alone. The IDS pseudogene — a partial copy of the active gene located nearby on the same chromosome — is responsible for one of the more common severe-form mutations, a recurring inversion/rearrangement that occurs when recombination takes place between the pseudogene and intron 7 of the active IDS gene. This mutation is consistently associated with the neuronopathic phenotype.

The X-linked recessive inheritance pattern creates a distinctive family dynamic: carrier mothers who show no symptoms can pass the condition to half their sons and carrier status to half their daughters, meaning that the first sign a family has of MPS II is often the diagnosis of an affected child. This is one of the reasons why genetic counselling and DNA sequencing for carrier detection in at-risk families are so important — they can identify carrier women who might otherwise have no reason to suspect they carry the faulty IDS gene, giving them the opportunity to make informed reproductive decisions and ensuring that any future affected sons are identified and treated as early as possible. The de novo mutation rate of approximately 25% also means that families with no prior history of MPS II can still have an affected child, making newborn screening the only reliable population-level tool for early identification.

MPS 2 Disease Newborn Screening and Awareness Statistics US

Source: Genetics in Medicine PMC (2023 — NBS recommendation); HRSA Newborn Screening page; PMC Illinois NBS update; ScienceDirect sibling pair timing study (2022); Baby’s First Test / HRSA; NCBI GeneReviews (January 2025); National MPS Society; Hunter Outcome Survey (NCT03292887)

The August 2022 addition of MPS II to the Recommended Uniform Screening Panel (RUSP) was the result of years of advocacy, clinical evidence-building, and policy work, and it happened in large part because the treatment landscape had evolved to the point where finding a child early made a demonstrable difference to outcomes. When no effective treatment existed, there was less urgency to screen; once idursulfase became available in 2006 and evidence accumulated that starting it before symptoms appeared was far better than waiting for clinical diagnosis, the argument for newborn screening became compelling and eventually overwhelming. The Illinois experience is particularly instructive: by detecting MPS II at birth and starting infants on ERT at 4 and 6 weeks of age — compared to the typical diagnosis age of over 3 years in the general population — the screening programme gave those children a head start measured not in weeks but in years of protected development.

The sibling pair data is perhaps the most visceral illustration of why early diagnosis matters so much. In published case reports, brothers with identical or near-identical MPS II mutations treated at different ages consistently show that the younger-treated sibling has meaningfully better outcomes: less joint disease, less cardiac valve thickening, less cognitive impact, better mobility. One study found that outcomes after 5–8 years of ERT were significantly more favourable across all clinical parameters for patients who began treatment before 18 months of age. That 18-month threshold is not arbitrary — it reflects the window before significant irreversible organ and neurological damage accumulates. Every month of delay in diagnosis and treatment is, for a child with severe MPS II, a month of GAG accumulation that current therapy cannot undo. Newborn screening, now recommended nationally, is the only tool that systematically eliminates that delay.

Disclaimer: The data reports published on The Global Files are sourced from publicly available materials considered reliable. While efforts are made to ensure accuracy, no guarantees are provided regarding completeness or reliability. The Global Files is not liable for any errors, omissions, or damages resulting from the use of these reports.